Search results
Added:
1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter aortic valve replacement (TAVR) compared to surgical aortic valve replacement (SAVR) in female patients with severe aortic stenosis.Dr Didier Tchétché (Clinique Pasteur, FR) joins us onsite at TCT Conference to discuss the pooled findings from the RHEIA (NCT04160130) and PARTNER 3 (NCT02675114) trials.RHEIA and PARTNER 3 are…
View more
Added:
3 months ago
TCT 2025 - Long-term follow-up of the PARTNER 3 trial showed no safety concerns for transcatheter aortic-valve replacement (TAVR) compared to surgical treatment of aortic stenosis (AS).Dr Michael Mack (Baylor Scott & White Heart Hospital, Plano, US) joins us to share the clinical and echocardiographic outcomes from the seven-year follow-up of the PARTNER 3 low-risk randomised trial (NCT02675114)…
View more
Added:
2 years ago
TCT 23 - In this short virtual interview, we are joined by Dr Martin B Leon (Columbia University Medical Center, US) to discuss the 5-year outcomes from Edwards' PARTNER 3 low-risk trial (NCT02675114).PARTNER 3 is a randomized, prospective, multicenter trial that aimed to determine the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients with severe calcific aortic…
View more
Added:
1 week ago
Added:
1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter aortic valve replacement (TAVR) in addition to optimal heart failure therapy (OHFT) compared to OHFT alone in patients with heart failure and moderate aortic stenosis.Dr Nicolas M Van Mieghem (Erasmus University Medical Center, Rotterdam, NL) joins us onsite at TCT Conference to discuss the findings from TAVR UNLOAD (NCT02661451)…
View more
Added:
2 years ago
In this video series, first presented at the ESC Congress 2023 held in Amsterdam, Prof Roxana Mehran, Dr Antoinette Neylon, Dr Martin Swaans, Prof Raphael Rosenhek and Prof Haim Danenberg discuss the Expand II TAVR pivotal trial design and the rational for investigating the treatment of moderate aortic stenosis patients with Evolut™ TAVI, provide practical Echo imaging recommendations to improve…
View more
Added:
1 week ago
Arrhythmia Academy Editor-in-Chief Dr Luigi Di Biase shares his expert perspective on the most practice-changing clinical trials emerging from the latest advances in atrial fibrillation management.In this highlights discussion, Dr Di Biase distills the key evidence that is reshaping clinical decision-making in AF ablation, anticoagulation strategies, and rhythm control approaches. Drawing from…
View more
Added:
11 months ago
CRT 25 - Dr S. Chris Malaisrie (Northwestern University, Evanston, US) joins us to discuss the five-year outcomes from the PARTNER 3 aortic valve-in-valve registry (NCT02675114). The prospective, randomized, multi-center study aimed to assess TAVR with the Edwards SAPIEN 3 transcatheter heart valve (Edwards Lifesciences) compared to aortic valve replacement with a commercially available surgical…
View more
Innovation and Development of PHV TAVR
Added:
3 months ago
Review Article
Added:
1 day ago
Source:
Transcatheter Academy
One-year outcomes from the LANDMARK trial show the Myval transcatheter heart valve (THV) series is noninferior to contemporary THVs for treating symptomatic severe native aortic stenosis.¹ The results demonstrate comparable clinical efficacy and haemodynamic performance at 1 year.MethodologyLANDMARK (NCT04275726) was a prospective, randomised, open-label, noninferiority trial conducted across 31…
View more